Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Improving Clinical and Economic Outcomes in Hyperkalemia: Managed Care Considerations for Pharmacy Professionals

Credits Available
Pharmacists: 1.5 contact hours (0.15 CEUs)
Released: May 12, 2022 Expiration: May 11, 2023
Start Activity
Provided by ProCE, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
AstraZeneca
Katherine Di Palo, PharmD
Michelle Richardson, PharmD, BCPS

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Identify causes, risk factors, clinical complications, and economic consequences of hyperkalemia
  • Evaluate traditional and novel treatment options for hyperkalemia, including the efficacy and safety of available agents
  • Design safe and effective treatment plans for hyperkalemia with an oral potassium binder

Information on this Educational Activity

ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Katherine Di Palo, PharmD

Assistant Professor of Medicine
Hospital Medicine
Albert Einstein College of Medicine
Clinical Program Manager
Hospital Readmissions Reduction Program
Montefiore Medical Center
Bronx, New York

Katherine Di Palo, PharmD, FAHA, FHFSA, BCACP, BCGP, has disclosed that she has received consulting fees and funds for research support from Vifor.
Michelle Richardson, PharmD, BCPS

Assistant Professor
Tufts University School of Medicine
Special and Scientific Staff
William B Schwartz Division of Nephrology
Tufts Medical Center
Boston, Massachusetts

Michelle Richardson, PharmD, BCPS, has disclosed that she receives salary from Dialysis Clinic, Inc.

Staff

ProCE
ProCE staff and planners have no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

The target audience for this activity is pharmacists, including managed care, specialty, and clinical pharmacists, who care for patients with or at risk for hyperkalemia as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice.

Goal

The goal of this activity is to improve the knowledge and competence of learners about the causes, risk factors, and clinical complications of hyperkalemia, novel treatment options for hyperkalemia, and the necessary information to design safe and effective treatment plans for patients with hyperkalemia.

Pharmacist Continuing Education

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-125-H01-P has been assigned to this home study, knowledge-based activity. This activity is approved for 1.5 contact hours (0.15 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of an evaluation and post-test with a score of 65% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 12, 2022, through May 11, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Improving Clinical and Economic Outcomes in Hyperkalemia: Managed Care Considerations for Pharmacy Professionals

Loading...
Interactive on-demand webinar featuring expert insights into the management of hyperkalemia to improve clinical and economic outcomes.
Katherine Di Palo, PharmD
Michelle Richardson, PharmD, BCPS
Pharmacists: 1.5 contact hours (0.15 CEUs)
Released: May 12, 2022 Expiration: May 11, 2023

Related Content

Dr. Katherine Di Palo discusses use of novel potassium binders for the management of hyperkalemia, from ProCE

Katherine Di Palo, PharmD Released: May 13, 2022

Downloadable slides featuring expert insights on the burden of and screening methods for undiagnosed NVAF from ProCE

Stephanie Dwyer Kaluzna, PharmD, BCCP Kathleen A. Lusk, PharmD, BCPS, BCCP Released: April 13, 2022

Concise microlearning module featuring expert insight on the use of DOAC therapy in NVAF for stroke prevention from ProCE

Stephanie Dwyer Kaluzna, PharmD, BCCP Kathleen A. Lusk, PharmD, BCPS, BCCP Pharmacists: 0.5 contact hours (0.05 CEUs) Released: April 13, 2022 Expired: April 12, 2023

A quick reference guide for the screening and management of NVAF, from ProCE

Stephanie Dwyer Kaluzna, PharmD, BCCP Kathleen A. Lusk, PharmD, BCPS, BCCP Released: April 13, 2022
Provided by ProCE, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
AstraZeneca

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings